| Detailed information |
|---|
| CancerLivER ID | 2219 |
| Biomarker | AFP, GGT, ALT, AST |
| Biomarker Name/Symbol (given in Publication) | AFP, GGT, ALT, AST |
| Biomolecule | Protein |
| Subject | Male Sprague-Dawley rats |
| Degree of Validity | Potential Diagnostic marker for HCC; but not validated on human patient cohort |
| Experimental Condition | HCC v/s Normal/treated with AEA; associated with progression |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated |
| Level of significance | p < 0.0001 |
| Source | Serum |
| PMID | 28900384 |
| Type of Biomarker | Potential Prognostic * |
| Pathway | cell proliferation and an immunosuppressive activity |
| Cohort | Male Sprague-Dawley rats: experimental model of HCC was induced in rats by DEN as the initiator and 2-AAF as the promoter of hepatocarcinogenesis ; six different groups of six rats each (n = 6). Group 1 (Control) animals fed with standard diet and served as a normal control, which injected with the |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Rat HCC |
| Year of Publication | 2017 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT03645655,NCT03047603,NCT03460080,NCT03741088,NCT03132740 |